Steady‐state equilibrium phase inversion recovery ON‐resonant water suppression (IRON) MR angiography in conjunction with superparamagnetic nanoparticles. A robust technique for imaging within a wide range of contrast agent dosages. Issue 4 (15th February 2013)

• Record Type: Journal Article
• Authors: Gitsioudis, Gitsios; Stuber, Matthias; Arend, Ingolf; Thomas, Moritz; Yu, Jing; Hilbel, Thomas; Giannitsis, Evangelos; Katus, Hugo A.; Korosoglou, Grigorios
• Is Part Of: Journal of magnetic resonance imaging. Volume 38:Issue 4(2013)
• Page Start: 836
• Page End: 844
• Publication Date: 2013-02-15
• Subjects: Magnetic resonance imaging -- Periodicals; 616
• DOI: 10.1002/jmri.24043
• Languages: English
• ISSNs: 1053-1807

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jmri24043-sec-0001" sec-type="section"> <title>Purpose</title> <p>To investigate the ability of inversion recovery ON‐resonant water suppression (IRON) in conjunction with P904 (superparamagnetic nanoparticles which consisting of a maghemite core coated with a low‐molecular‐weight amino‐alcohol derivative of glucose) to perform steady‐state equilibrium phase MR angiography (MRA) over a wide dose range.</p> </sec> <sec id="jmri24043-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>Experiments were approved by the institutional animal care committee. Rabbits (n = 12) were imaged at baseline and serially after the administration of 10 incremental dosages of 0.57–5.7 mgFe/Kg P904. Conventional T<sub>1</sub>‐weighted and IRON MRA were obtained on a clinical 1.5 Tesla (T) scanner to image the thoracic and abdominal aorta, and peripheral vessels. Contrast‐to‐noise ratios (CNR) and vessel sharpness were quantified.</p> </sec> <sec id="jmri24043-sec-0003" sec-type="section"> <title>Results</title> <p>Using IRON MRA, CNR and vessel sharpness progressively increased with incremental dosages of the contrast agent P904, exhibiting constantly higher contrast values than T<sub>1</sub>‐weighted MRA over a very wide range of contrast agent doses (CNR of 18.8 ± 5.6 for IRON versus 11.1 ± 2.8 for T<sub>1</sub>‐weighted MRA at 1.71 mgFe/kg, <italic>P</italic> = 0.02 and 19.8 ± 5.9 for IRON versus −0.8 ± 1.4 for T<sub>1</sub>‐weighted MRA at 3.99 mgFe/kg, <italic>P</italic> = 0.0002). Similar results were obtained for vessel sharpness in peripheral vessels, (Vessel sharpness of 46.76 ± 6.48% for IRON versus 33.20 ± 3.53% for T<sub>1</sub>‐weighted MRA at 1.71 mgFe/Kg, <italic>P</italic> = 0.002, and of 48.66 ± 5.50% for IRON versus 19.00 ± 7.41% for T<sub>1</sub>‐weighted MRA at 3.99 mgFe/Kg, <italic>P</italic> = 0.003).</p> </sec> <sec id="jmri24043-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Our study suggests that quantitative CNR and vessel sharpness after the injection of P904 are consistently higher for IRON MRA when compared with conventional T<sub>1</sub>‐weighted MRA. These findings apply for a wide range of contrast agent dosages. J. Magn. Reson. Imaging 2013;38:836–844. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>